Vaccinated COVID-19 Index Cases Are Less Likely to Transmit SARS-CoV-2 to Their Household Contacts: A Cohort Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Participants
2.3. Questionnaire Design
2.4. Data Collection
2.5. Sampling and Sample Size
2.6. Statistical Analysis
2.7. Ethical Considerations
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bobrovitz, N.; Ware, H.; Ma, X.; Li, Z.; Hosseini, R.; Cao, C.; Selemon, A.; Whelan, M.; Premji, Z.; Issa, H.; et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: A systematic review and meta-regression. Lancet Infect. Dis. 2023, 23, 556–567. [Google Scholar] [CrossRef]
- Madewell, Z.J.; Yang, Y.; Longini, I.M.; Halloran, M.E.; Dean, N.E. Factors associated with household transmission of SARS-CoV-2: An Updated Systematic Review and Meta-analysis. JAMA Netw. Open 2021, 4, e2122240. [Google Scholar] [CrossRef] [PubMed]
- Martínez-Baz, I.; Trobajo-Sanmartín, C.; Burgui, C.; Casado, I.C.J. Transmission of SARS-CoV-2 infection and risk factors in a cohort of close contacts. Postgr Med. 2022, 134, 230–238. [Google Scholar] [CrossRef] [PubMed]
- Godoy, P.; García-cenoz, M.; Parron, I.; Carol, M.; Bes, N.; Soriano, N.; Guillaumes, M.; Plans, P.; Alseda, M.; Godoy, S.; et al. Factores asociados a la transmisión del SARS-CoV-2 en los domicilios: Una scoping review. Enf. Emerg. 2022, 21, 85–88. [Google Scholar]
- Harris, R.J.; Hall, J.A.; Zaidi, A.; Andrews, N.J.; Dunbar, J.K.; Dabrera, G. Effect of vaccination on household transmission of SARS-CoV-2 in England. N. Engl. J. Med. 2021, 385, 759–760. [Google Scholar] [CrossRef]
- Arabi, M.; Al-Najjar, Y.; Sharma, O.; Kamal, I.; Javed, A.; Gohil, H.S.; Paul, P.; Al-Khalifa, A.M.; Laws, S.A.; Zakaria, D. Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: A systematic review. BMC Infect. Dis. 2023, 23, 432. [Google Scholar] [CrossRef] [PubMed]
- Martínez-Baz, I.; Miqueleiz, A.; Egüés, N.; Casado, I.; Burgui, C.; Echeverría, A.; Navascués, A.; Fernández-Huerta, M.; Cenoz, M.G.; Trobajo-Sanmartín, C.; et al. Effect of COVID-19 vaccination on the SARS-CoV-2 transmission among social and household close contacts: A cohort study. J. Infect. Public. Health 2023, 16, 410–417. [Google Scholar] [CrossRef]
- Chung, H.; He, S.; Nasreen, S.; Sundaram, M.E.; Buchan, S.A.; Wilson, S.E.; Chen, B.; Calzavara, A.; Fell, D.B.; Austin, P.C.; et al. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: Test negative design study. BMJ 2021, 374, n1943. [Google Scholar] [CrossRef]
- Bernal, J.L.; Andrews, N.; Gower, C.; Robertson, C.; Stowe, J.; Tessier, E.; Simmons, R.; Cottrell, S.; Roberts, R.; O’Doherty, M.; et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study. BMJ 2021, 373, n1088. [Google Scholar] [CrossRef]
- Hall, V.; Foulkes, S.; Insalata, F.; Kirwan, P.; Saei, A.; Atti, A.; Wellington, E.; Khawam, J.; Munro, K.; Cole, M.; et al. Protection against SARS-CoV-2 after COVID-19 Vaccination and Previous Infection. N. Engl. J. Med. 2022, 386, 1207–1220. [Google Scholar] [CrossRef]
- Nordström, P.; Ballin, M.; Nordström, A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: A retrospective, total population cohort study in Sweden. Lancet Infect. Dis. 2022, 22, 781–790. [Google Scholar] [CrossRef]
- Lopez-Bernal, J.; Panagiotopoulos, N.; Byers, C.; Vilaplana, T.G.; Boddington, N.; Zhang, X.S.; Charlett, A.; Elgohari, S.; Coughlan, L.; Whillock, R.; et al. Transmission dynamics of COVID-19 in household and community settings in the United Kingdom, January to March 2020. Euro. Surveill. 2022, 27, 2001551. [Google Scholar] [CrossRef]
- Godoy, P.; Castilla, J.; Mayoral, J.M.; Delgado-Rodriguez, M.; Martin, V.; Astray, J.; Soldevila, N.; Gonzalez-Candelas, F.; Castro, A.; Baricot, M.; et al. Smoking may increase the risk of hospitalization due to influenza. Eur. J. Public. Health 2016, 26, 882–887. [Google Scholar] [CrossRef]
- Madewell, Z.J.; Yang, Y.; Longini, I.M.; Halloran, M.E.; Dean, N.E. Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: An updated systematic review and meta-analysis. JAMA Netw. Open 2022, 5, E229317. [Google Scholar] [CrossRef] [PubMed]
- López-Muñoz, I.; Torrella, A.; Pérez-Quílez, O.; Castillo-Zuza, A.; Martró, E.; Bordoy, A.E.; Saludes, V.; Blanco, I.; Soldevila, L.; Estrada, O.; et al. SARS-CoV-2 secondary attack rates in vaccinated and unvaccinated household contacts during replacement of Delta with Omicron variant, Spain. Emerg. Infect. Dis. 2022, 28, 1999–2008. [Google Scholar] [CrossRef]
- Thompson, H.A.; Mousa, A.; Dighe, A.; Fu, H.; Arnedo-Pena, A.; Barrett, P.; Bellido-Blasco, J.; Bi, Q.; Caputi, A.; Chaw, L.; et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) setting-specific transmission rates: A systematic review and meta-analysis. Clin. Infect. Dis. 2021, 73, E754–E764. [Google Scholar] [CrossRef] [PubMed]
- Eyre, D.W.; Taylor, D.; Purver, M.; Chapman, D.; Fowler, T.; Pouwels, K.B.; Walker, A.S.; Peto, T.E. Effect of COVID-19 vaccination on transmission of Alpha and Delta variants. N. Engl. J. Med. 2022, 386, 744–756. [Google Scholar] [CrossRef]
- Levine-Tiefenbrun, M.; Yelin, I.; Alapi, H.; Katz, R.; Herzel, E.; Kuint, J.; Chodick, G.; Gazit, S.; Patalon, T.; Kishony, R. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nat. Med. 2021, 27, 2108–2110. [Google Scholar] [CrossRef] [PubMed]
- Lyngse, F.P.; Mølbak, K.; Denwood, M.; Christiansen, L.E.; Møller, C.H.; Rasmussen, M.; Cohen, A.S.; Stegger, M.; Fonager, J.; Sieber, R.N.; et al. Effect of vaccination on household transmission of SARS-CoV-2 Delta variant of concern. Nat. Commun. 2022, 13, 3764. [Google Scholar] [CrossRef] [PubMed]
- de Gier, B.; Andeweg, S.; Joosten, R.; Ter Schegget, R.; Smorenburg, N.; van de Kassteele, J.; Hahné, S.J.; van den Hof, S.; de Melker, H.E.; Knol, M.J. Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021. Euro. Surveill. 2021, 26, 7–13. [Google Scholar] [CrossRef]
- Andrews, N.; Tessier, E.; Stowe, J.; Gower, C.; Kirsebom, F.; Simmons, R.; Gallagher, E.; Thelwall, S.; Groves, N.; Dabrera, G.; et al. Duration of protection against mild and severe disease by COVID-19 vaccines. N. Engl. J. Med. 2022, 386, 340–350. [Google Scholar] [CrossRef]
- Monge, S.; Rojas-Benedicto, A.; Olmedo, C.; Mazagatos, C.; Sierra, M.J.; Limia, A.; Martín-Merino, E.; Larrauri, A.; Hernán, M.A.; Moreno, D.; et al. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: A nationwide cohort study. Lancet Infect. Dis. 2022, 22, 1313–1320. [Google Scholar] [CrossRef] [PubMed]
- Suarez-Castillo, S.; Khaoua, H.; Courtejoie, N. Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022. Euro. Surveill. 2022, 27, 2200250. [Google Scholar] [CrossRef]
- Castilla, J.; Lecea, Ó.; Salas, C.M.; Quílez, D.; Miqueleiz, A.; Trobajo-Sanmartín, C.; Navascués, A.; Martínez-Baz, I.; Casado, I.; Burgui, C.; et al. Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022. Euro. Surveill. 2022, 27, 2200619. [Google Scholar] [CrossRef] [PubMed]
- Meyerowitz, E.A.; Richterman, A.; Gandhi, R.T.; Sax, P.E. Transmission of SARS-CoV-2: A review of viral, host, and environmental factors. Ann. Intern. Med. 2021, 174, 69–79. [Google Scholar] [CrossRef] [PubMed]
- Trunfio, M.; Richiardi, L.; Alladio, F.; Staffilano, E.; Longo, B.; Venuti, F.; Ghisetti, V.; Burdino, E.; Bonora, S.; Vineis, P.; et al. Determinants of SARS-CoV-2 contagiousness in household contacts of symptomatic adult index cases. Front. Mircrobiol. 2022, 13, 829393. [Google Scholar] [CrossRef] [PubMed]
- Altarawneh, H.N.; Chemaitelly, H.; Ayoub, H.H.; Tang, P.; Hasan, M.R.; Yassine, H.M.; Al-Khatib, H.A.; Smatti, M.K.; Coyle, P.; Al-Kanaani, Z.; et al. Effects of previous infection and vaccination on symptomatic Omicron infections. N. Engl. J. Med. 2022, 387, 21–34. [Google Scholar] [CrossRef] [PubMed]
- Tan, C.Y.; Chiew, C.J.; Pang, D.; Lee, V.J.; Ong, B.; Lye, D.C.; Tan, K.B. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: A national cohort study. Lancet Infect. Dis. 2023, 23, 799–805. [Google Scholar] [CrossRef]
- Ellingson, K.D.; Hollister, J.; Porter, C.J.; Khan, S.M.; Feldstein, L.R.; Naleway, A.L.; Gaglani, M.; Caban-Martinez, A.J.; Tyner, H.L.; Lowe, A.A.; et al. Risk factors for reinfection with SARS-CoV-2 Omicron variant among previously infected frontline workers. Emerg. Infect. Dis. 2023, 29, 599–604. [Google Scholar] [CrossRef]
- Miyahara, R.; Tamura, K.; Kato, T.; Nakazaki, M.; Otani, K.; Ko, Y.K.; Kamigaki, T.; Arima, Y.; Tani, H.; Oishi, K.; et al. SARS-CoV-2 variants and age-dependent infection rates among household and nonhousehold contacts. Emerg. Infect. Dis. 2023, 29, 1648–1650. [Google Scholar] [CrossRef]
- Feikin, D.R.; Higdon, M.M.; Abu-Raddad, L.J.; Andrews, N.; Araos, R.; Goldberg, Y.; Groome, M.J.; Huppert, A.; O’Brien, K.L.; Smith, P.G.; et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: Results of a systematic review and meta-regression. Lancet 2022, 399, 924–944. [Google Scholar] [CrossRef] [PubMed]
- Stein, C.; Nassereldine, H.; Sorensen, R.J.; Amlag, J.O.; Bisignano, C.; Byrne, S.; Castro, E.; Coberly, K.; Collins, J.K.; Dalos, J.; et al. Past SARS-CoV-2 infection protection against re-infection: A systematic review and meta-analysis. Lancet 2023, 401, 833–842. [Google Scholar] [CrossRef] [PubMed]
- Johnson, A.G.; Linde, L.; Ali, A.R.; DeSantis, A.; Shi, M.; Adam, C.; Armstrong, B.; Armstrong, B.; Asbell, M.; Auche, S.; et al. COVID-19 Incidence and mortality among unvaccinated and vaccinated persons aged ≥ 12 years by receipt of bivalent booster doses and time since vaccination—24 U.S. jurisdictions, October 3, 2021–December 24, 2022. MMWR Morb. Mortal. Wkly. Rep. 2023, 72, 145–152. [Google Scholar] [CrossRef] [PubMed]
Variable | Infected Contacts n = 87 | Total Contacts n = 234 | SAR (%) |
---|---|---|---|
Age group (years) | |||
0–17 | 9 | 50 | 18.0 |
18–44 | 16 | 50 | 32.0 |
45–64 | 30 | 85 | 35.3 |
≥65 | 32 | 49 | 65.3 |
Sex | |||
Male | 44 | 119 | 37.0 |
Female | 43 | 115 | 37.4 |
Index case vaccination | |||
Yes | 75 | 215 | 34.9 |
No | 12 | 19 | 63.2 |
Contact with previous COVID-19 history | |||
Yes | 30 | 111 | 27.0 |
No | 57 | 123 | 46.3 |
Smoker | |||
Yes | 36 | 70 | 51.4 |
No | 51 | 164 | 31.1 |
Contact vaccination ≥ 1 dose | |||
Yes | 82 | 218 | 37.6 |
No | 5 | 16 | 31.2 |
Cohabitation with partner | |||
Yes | 52 | 105 | 49.5 |
No | 35 | 129 | 27.1 |
Shared bedroom | |||
Yes | 40 | 90 | 44.4 |
No | 47 | 144 | 32.6 |
Face mask use | |||
Yes | 34 | 80 | 42.5 |
No | 53 | 154 | 34.4 |
Total | 87 | 234 | 37.2 |
Variable | Infected Contacts n = 74 | Non-Infected Contacts n = 121 | OR | 95% CI | p-Value |
---|---|---|---|---|---|
Age ± SD | 53.1 ± 21.0 | 39.0 ± 21.8 | 1.04 | <0.001 | |
Age group (years) | |||||
0–17 | 9 | 41 | 1.00 | ||
18–44 | 16 | 34 | 2.14 | 0.84–5.45 | 0.109 |
45–64 | 30 | 55 | 2.48 | 1.06–5.80 | 0.035 |
≥65 | 32 | 17 | 8.57 | 3.38–21.75 | <0.001 |
Sex | |||||
Male | 44 | 75 | 0.98 | 0.58–1.67 | 0.947 |
Female | 43 | 72 | 1.00 | ||
Index case vaccination | |||||
Yes | 75 | 140 | 0.31 | 0.11–0.82 | 0.014 |
No | 12 | 7 | 1.00 | ||
Previous COVID-19 history | |||||
Yes | 30 | 81 | 0.43 | 0.25–0.74 | 0.002 |
No | 57 | 66 | 1.00 | ||
Smoker | |||||
Yes | 36 | 34 | 2.34 | 1.32–4.16 | 0.003 |
No | 51 | 113 | 1.00 | ||
Contact vaccination ≥ 1 dose | |||||
Yes | 82 | 136 | 1.32 | 0.44–3.95 | 0.611 |
No | 5 | 11 | |||
Cohabitation with partner | |||||
Yes | 52 | 53 | 2.63 | 1.52–4.54 | <0.001 |
No | 35 | 94 | 1.00 | ||
Shared bedroom | |||||
Yes | 40 | 50 | 1.65 | 0.96–2.84 | 0.069 |
No | 47 | 97 | 1.00 | ||
Face mask use | |||||
Yes | 34 | 46 | 1.40 | 0.81–2.45 | 0.225 |
No | 53 | 101 | 1.00 |
Variable | aOR | 95% CI | p-Value |
---|---|---|---|
Age group (years) | |||
0–17 | 1.00 | ||
18–44 | 1.41 | 0.47–4.23 | 0.541 |
45–64 | 1.14 | 0.38–3.39 | 0.819 |
≥65 | 3.34 | 1.00–11.18 | 0.050 |
Sex | |||
Male | 0.68 | 0.36–1.29 | 0.239 |
Female | 1.00 | ||
Index case vaccination | |||
Yes | 0.21 | 0.07–0.67 | 0.008 |
No | 1.00 | ||
Contact with previous COVID-19 history | |||
Yes | 0.43 | 0.23–0.81 | 0.009 |
No | 1.00 | ||
Contact vaccination ≥ 1 dose | |||
Yes | 0.95 | 0.23–3.80 | 0.938 |
No | 1.00 | ||
Smoker | |||
Yes | 2.32 | 1.18–4.54 | 0.014 |
No | 1.00 | ||
Cohabitation with partner | |||
Yes | 2.34 | 1.08–5.09 | 0.031 |
No | 1.00 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Godoy, P.; Martínez-Baz, I.; Parron, I.; García-Cenoz, M.; Ferras, J.; Carol, M.; Bes, N.; Guillaumes, M.; Godoy, S.; Toledo, D.; et al. Vaccinated COVID-19 Index Cases Are Less Likely to Transmit SARS-CoV-2 to Their Household Contacts: A Cohort Study. Vaccines 2024, 12, 240. https://doi.org/10.3390/vaccines12030240
Godoy P, Martínez-Baz I, Parron I, García-Cenoz M, Ferras J, Carol M, Bes N, Guillaumes M, Godoy S, Toledo D, et al. Vaccinated COVID-19 Index Cases Are Less Likely to Transmit SARS-CoV-2 to Their Household Contacts: A Cohort Study. Vaccines. 2024; 12(3):240. https://doi.org/10.3390/vaccines12030240
Chicago/Turabian StyleGodoy, Pere, Iván Martínez-Baz, Ignasi Parron, Manuel García-Cenoz, Joaquim Ferras, Mònica Carol, Nuria Bes, Montserrat Guillaumes, Sofia Godoy, Diana Toledo, and et al. 2024. "Vaccinated COVID-19 Index Cases Are Less Likely to Transmit SARS-CoV-2 to Their Household Contacts: A Cohort Study" Vaccines 12, no. 3: 240. https://doi.org/10.3390/vaccines12030240
APA StyleGodoy, P., Martínez-Baz, I., Parron, I., García-Cenoz, M., Ferras, J., Carol, M., Bes, N., Guillaumes, M., Godoy, S., Toledo, D., Follia, N., Miret, C., Pardos, J., Alsedà, M., Plans-Rubio, P., Sanz, I., Sala, M. -R., Caylà, J. A., Mendioroz, J., ... on behalf of the SARS-CoV-2 Transmission to Household Contacts Working Group. (2024). Vaccinated COVID-19 Index Cases Are Less Likely to Transmit SARS-CoV-2 to Their Household Contacts: A Cohort Study. Vaccines, 12(3), 240. https://doi.org/10.3390/vaccines12030240